Evaluation of the Efficacy of Ophthacare eye drops in Inflammatory and Infectious Ophthalmic Conditions

Two hundred and thirty eight patients with ocular symptoms of conjunctivitis, conjunctival xerosis, pterygium and pinguecula were selected for this clinical trial. All the patients were administered Ophthacare eye drops topically as a single medication at the dose of 2 drops every 2 hours for 15 days. Ophthacare eye drops showed excellent results in relieving symptoms of viral conjunctivitis in 93.87% of the patients and 77.77% of the patients with acute allergic conjunctivitis. The response to treatment in bacterial conjunctivitis was slower. Ophthacare also relieved the inflammatory symptoms of pterygium and pinguecula. There were no side effects reported by patients during the course of the study. The open clinical trial conducted at BRD Medical College, Gorakhpur, confirmed the efficacy and safety of Ophthacare eye drops.